Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

WHO emphasizes integrating surveillance into national STI programs. Zoliflodacin, a novel antimicrobial agent, shows promise in treating gonorrhea, demonstrating non-inferiority to ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Deniz Gökengin thinks colleagues view her as “a very serious, hardworking, meticulous, control-freak type of person”. But she ...

The investigational oral therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor, in a single tablet ...

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Merck on Wednesday said the Phase 3 study of the once-daily, two-drug single-tablet regimen met the success criterion for its primary efficacy hypothesis, showing non-inferiority to the three-drug ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Merck (MRK) stock gains as new oral HIV tablet matches Gilead's (GILD) three-drug once-daily HIV pill Biktarvy in a Phase 3 ...